Experts accredited in genetic diagnostic testing of inherited diseases

Health [in] Code is authorized as a clinical laboratory by Xunta de Galicia and is registered in the corresponding registry under no. C-15-002226

CLIA (Clinical Laboratory Improvement Amendments)

Awarded by the US federal government’s Centers for Medicare & Medicaid Services (CMS).


Quality assurance and technical competence [downloadable technical appendix]:


Quality management system:


As members of the European Molecular Genetics Quality Network (EMQN, UK) and the Genomics Quality Assessment (GenQA, UK), we successfully participate in their annual interlaboratory programs (technical and disease-specific external quality assessment schemes, EQA) related to inherited cardiovascular, neurological and immune diseases as well as hereditary cancer. The excelence of our quality assurance program has been acknowledged by The College of American Pathologists (CAP, US) for our continuous improvement in quality through participation in proficiency testing (CAP # 8280234-01).


Quality control at Health in Code is understood as management of the performance of the pre-analytical, analytical and post-analytical stages of the clinical laboratory process; which includes monitoring the test methodologies and specifications, reagents, equipment, sample handling, test reporting, internal and external audits to ensure the continuous high quality of testing.

Health in Code performs analytic validation studies following the guidelines from the EuroGentest Group and the ACMG (American College of Medical Genetics), in accordance with the requirements of UNE-EN ISO 15189 quality standard for clinical laboratories. Analityc validity of Health in Code’s NGS panels has been demostrated for SNPs and INDELs (≤20 pb) utilizing a standard reference sample NA 12878 (Coriell Cell Repositories, NJ) with results yielding on average: 1.000 sensitivity, 1.000 specificity and 0.999 accuracy for both SNPs and INDELs; as well as high repeteability and reproducibility scores (≈96%) for variant detection. In addition, Sanger sequencing is used to confirm those clinically relevant variants obtained with suboptimal quality parameters, as well as variants located in low coverage regions.


  • Innovative SME Award 2016.
  • Seal of Excellence: Certificate delivered by the European Commission as managing institution for Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020. Project proposal no. 729192, HIC-SW_HIC-Software: A new Laboratory Management System (LIMS) for genetics.



Select the panel you wish to request

Required document in order to perform the study

Variant classification and clinical usefulness criteria

This website uses cookies for the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and acceptance of our cookies policy, click on the link for more information

The cookie settings of this website are configured to "allow cookies" and thus offer you the best possible browsing experience. If you continue using this website without changing your cookie settings or clicking "Accept" you will be giving your consent to this.